Accounting for noncompliance in pharmacoeconomic evaluations

PharmacoEconomics

Volumn 19, Issue 12, 2001, Pages 1185-1197

  Hughes, Dyfrig A ^a   Bagust, Adrian ^a   Haycox, Alan ^a   Walley, Tom ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ACCOUNTING; COST BENEFIT ANALYSIS; HUMAN; PATIENT COMPLIANCE; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

EID: 0035692607     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119120-00001     Document Type: Review

References (47)

1. Cost-effectiveness comparisons using 'real world' randomized trials: The case of new antidepressant drugs
2. Generalisation from phase III clinical trials: Survival, quality of life, and health economics
3. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data
4. Effectiveness of antihyperlipidemic drug management in clinical practice
5. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect rates in primary care settings?
6. Pharmacoeconomic evaluations in the real world: Effectiveness versus efficacy studies
7. Drug compliance in therapeutic trials: A review
8. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens
9. Primary non-compliance with prescribed medications in primary care
10. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals
11. The electronic medication event monitor: Lessons for pharmacotherapy
12. A systematic review of the associations between dose regimens and medication compliance
13. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
14. Cholesterol-reduction intervention study (CRIS): A randomized trial to assess effectiveness and costs in clinical practice
15. Apparent discontinuation rates in patients prescribed lipid-lowering drugs
16. Persistence of use of lipid-lowering medications: A cross-national study
17. Discontinuation rates of cholesterol-lowering medications: Implications for primary care
18. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
19. Measurement of patient compliance
20. Medication compliance as a feature in drug development
21. The natural history of medication compliance in a drug trial: Limitations of pill counts
22. Time to stop counting the tablets?
23. Ascertaining how much compliance is enough with outpatient antibiotic regimens
24. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
25. Cost-effectiveness of new treatments for overactive bladder, the example of tolterodine, a new muscarinic agent: A Markov model
26. Hepatitis C: An economic evaluation of extended treatment with interferon
27. The relative risk of incident coronary heart disease associated with recently stopping the use of β-blockers
28. Patient compliance and drug failure in protease inhibitor monotherapy
29. Erratic compliance with prescribed drug regimens: Target for drug delivery systems
30. Discontinuation symptoms and psychotropic drugs
31. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature
32. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens
33. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy
34. Modelling in economic evaluation: An unavoidable fact of life
35. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis
36. Patient compliance with drug therapy for diabetic nephropathy
37. Chronobiology: Suggestions for integrating it into drug development
38. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data
39. The impact of patient compliance on drug concentration profile in multiple doses
40. A Markov mixed effect regression model for drug compliance
41. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling
42. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling
43. Clinical trial simulations
44. The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies
45. Adherence and drug resistance: Predictions for therapy outcome